SFN

Create a new post for topic
Join the Conversation on
37 people
0 stories
5 posts
Explore Our Newsletters
What's New in
All
Stories
Posts
Videos
Latest
Trending
Post

I'm New Here!

I am a 41 year old single mom of three amazing sons and a chronic illness warrior. I have been diagnosed with Small Fiber Neuropathy (SFN), Rheumatoid Arthritis(RA), Chronic Fatigue Syndrome, Irritable Bowel Syndrome (IBS), Reynard’s Disease, Hashimoto’s, Exocrine pancreatic insufficiency(EPI), chronic pain, migraines, and daily chronic headaches and anxiety. I have an upcoming appointment at the end of August to see a cardiologist as I have had two abnormal EKGs. #MightyTogether #HashimotosThyroiditis #SFN #RheumatoidArthritis #ChronicFatigue #ChronicDailyHeadache #ExocrinePancreaticInsufficiency #IrritableBowelSyndromeIBS #ChronicIllness #ChronicPain #Migraine #Anxiety

Most common user reactionsMost common user reactions 11 reactions 4 comments
Post
See full photo

I Just Want My People To Understand What My Everydays Are Like…

I’m not new here, but this is my first time expressing myself. I was first Dx w/ Fibromyalgia in 2013, I didn’t let it define me! I was hit hard in 2018 with #Gastroparesis . A few months later, Hypermobile Ehlers Danlos Syndrome (although I knew I had #hypermobileehlers-DanlosSyndrome(hEDS), I just didn’t know it was a disease… I was a gymnast childhood - early HS). Then came one diagnosis after another. Whammo!!! #POTS , #MCAS , Small Fiber Neuropathy, etc,. So from 2018-Present. I have 15 confirmed diagnosed chronic diseases. I have not driven in a little over 2 yrs b/c of POTS & fainting, & it really sucks!!
All of my local friends have gone. My college roommates (7) & I have a daily group chat going. Nobody (1 roommate does) ever checks in with me to see how I am. Everyday I’m completely #Fatigued . I have #ChronicPain everywhere!!! I’m #nauseous . I have #chronicdiarrhea & #chronicconstipation . I have #ChronicMigraines It hurts to walk. The rapid electric zaps from the #SFN is excruciatingly painful. My #RheumatoidArthritis & my #Osteoarthritis & now #Facetarthritis in my cervical spine has become so debilitating.

I don’t want to be a downer, but I would friends/family just to text & say "Hi, I was just thinking about you, I hope today is better than yesterday… remember I always love you!" This way they don’t have to ask how I am doing, thereby don’t get an answer full of negativity, but at least I know that I’m still in their thoughts!

I’m angry. I’m depressed. I’m sad. I’m lonely. I’m #housebound . I’m bored.

Being #chronicallyill totally sucks! Yeah, I’m having another #pityparty

Most common user reactionsMost common user reactionsMost common user reactions 32 reactions 13 comments
Post

We are finally getting national attention!#ComplexRegionalPainSyndrome #SmallFiberNeuropathy

SIGN THE PETITION! ppls.ac/jenncare PLEASE SHARE!

UnitedHealthcare Bragged about $8.1 B in profit in 3 mos. made from people who pay them for health coverage. Their money model relies on denying people care–like Rights & Democracy NH member Jenn, who needs the care to manage serious illness.

SIGN THE PETITION ppls.ac/jenncare ! PLEASE SHARE!

#careovercost #CRPS #crpsawareness #CRPSWarrior #SFN #SmallFiberNeuropathy #peopleoverprofit

www.youtube.com/watch

Demand that United Healthcare pay for Jenn’s life-saving treatment

Our friend Jenn Coffey, a member of Rights & Democracy from Manchester, New Hampshire, has spent 20 years of her life providing medical assistance to patients as an EMT and LNA in ambulances and emergency departments alike. Now, she’s in severe need of medical assistance herself but, faces resistance and outright denials from her private health insurance company, United Healthcare. Jenn has a United Healthcare Medicare (dis)Advantage plan. Coffey first got cancer when she was 30 in 2014 and again at 42 and had to undergo a mastectomy and reconstruction at the same time. As a result of her cancer treatments, she now suffers from Complex Regional Pain Syndrome (CRPS) which causes intense pain that has kept her in the hospital for weeks at a time. There is currently no known cure for CRPS, but doctors have found ways to alleviate the pain for patients. Coffey needs ketamine infusions, and low dose naltrexone for her pain and long acting mestinon for vision and mental clarity . But she’s unable to pay for them, and has already sold most of her belongings to be able to pay for some of her treatments. United Healthcare refuses to cover these medications despite them being commonly prescribed to treat pain. “When I worked in medicine, I never imagined not treating a patient. [Someone] needs something, you go get it for them. But now, being on this side, I can’t access the same health care that I worked to get,” Coffey said. As a result of her conditions, she has not been able to work and relies on small SSI disability checks that cannot possibly cover her necessities. Coffey’s rent alone increased $400 last year. “There are treatments and things that can be done, but they’re held away from me by denials from United Healthcare not allowing me to have access to treatments. I have suffered so incredibly that I was in the hospital all the time, every month.” Now Coffey is forced to borrow money and sell more of her belongings to stay alive. United Healthcare, profited $20.1 billion last year alone. Now they are refusing to cover life-saving medical treatments for a policyholder who cannot pay. “If I don’t buy the treatment, I die.” Coffey said.
Post
See full photo

SMALL FIBER NEUROPATHY RESEARCH🔥

Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial (de Greef et al.,2016)

Small fiber neuropathy is the most common cause of neuropathic pain in peripheral neuropathies, with a minimum prevalence of 53/100,000. Patients experience excruciating pain, and currently available anti-neuropathic and other pain drugs do not relieve the pain substantially. Several open-label studies have suggested an immunological basis in small fiber neuropathy and have reported efficacy of treatment with intravenous immunoglobulin. Therefore, immunological mechanisms conceivably may play a role in small fiber neuropathy. To date, no randomized controlled study with intravenous immunoglobulin in patients with small fiber neuropathy has been performed.

Intravenous immunoglobulin therapy for small fiber neuropath...

#EMWarriors #Erythromelalgia #SmallFiberNeuropathy #ChronicPain #SFN

Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial - Trials

Background Small fiber neuropathy is the most common cause of neuropathic pain in peripheral neuropathies, with a minimum prevalence of 53/100,000. Patients experience excruciating pain, and currently available anti-neuropathic and other pain drugs do not relieve the pain substantially. Several open-label studies have suggested an immunological basis in small fiber neuropathy and have reported efficacy of treatment with intravenous immunoglobulin. Therefore, immunological mechanisms conceivably may play a role in small fiber neuropathy. To date, no randomized controlled study with intravenous immunoglobulin in patients with small fiber neuropathy has been performed. Methods/design This study is a randomized, double-blind, placebo-controlled, clinical trial in patients with idiopathic small fiber neuropathy. The primary objective is to investigate the efficacy of intravenous immunoglobulin versus placebo on pain alleviation. A 1-point change in the PI-NRS compared to baseline is considered the minimum clinically important difference. In the IVIg-treated group, we assume a response rate of approximately 60 % based on the criteria composed by the IMMPACT group for measurement of pain. Based on this, a sample size of 60 patients is needed. Eligible patients fulfilling the inclusion/exclusion criteria will be randomized to receive either intravenous immunoglobulin or placebo (0.9 % saline). The treatment regimen will start with a loading dose of 2 g/kg body weight over 2–4 consecutive days, followed by a maintenance dose of 1 g/kg body weight over 1–2 consecutive days given three times at a 3-week interval. The primary endpoint is the comparison of the percentage of responder subjects between the two treatment groups from the first randomization during the 12 weeks of treatment. A responder is defined as ≥ 1-point Pain Intensity Numerical Rating Scale improvement on the mean weekly peak pain relative to baseline. The secondary outcomes are pain intensity, pain qualities, other small fiber neuropathy-related complaints, daily and social functioning, as well as quality of life. In addition, safety assessments will be performed for adverse events, vital signs, and laboratory values outside the normal range. Responders during the 12-week treatment period will be followed during a 3-month extension phase. Discussion This is the first randomized, double-blind, placebo-controlled clinical trial with intravenous immunoglobulin in patients with idiopathic small fiber neuropathy. Positive findings will result in a new treatment option for small fiber neuropathy and support an immunological role in this condition. Trial registration ClinicalTrials.gov, NCT02637700 . Registered on 16 December 2015.
Most common user reactions 1 reaction